FCGR3A and coronary artery disorder: In addition, Höpfner et al. (2019) and Rogacev et al. (2012) have shown that absolute blood counts of CD14/CD16 (CD16A and CD16B, collectively CD16, are also known as FCGR3A and FCGR3A, respectively) double-positive monocytes can predict major adverse cardiac events in coronary artery disease patients.